Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is a lethal brain tumour in adults and children. However, DNA copy number and gene expression signatures indicate differences between adult and paediatric cases. To explore the genetic events underlying this distinction, we sequenced the exomes of 48 paediatric GBM samples. Somatic mutations in the H3.3-ATRX-DAXX chromatin remodelling pathway were identified in 44% of tumours (21/48). Recurrent mutations in H3F3A, which encodes the replication-independent histone 3 variant H3.3, were observed in 31% of tumours, and led to amino acid substitutions at two critical positions within the histone tail (K27M, G34R/G34V) involved in key regulatory post-translational modifications. Mutations in ATRX (α-thalassaemia/mental retardation syndrome X-linked) and DAXX (death-domain associated protein), encoding two subunits of a chromatin remodelling complex required for H3.3 incorporation at pericentric heterochromatin and telomeres, were identified in 31% of samples overall, and in 100% of tumours harbouring a G34R or G34V H3.3 mutation. Somatic TP53 mutations were identified in 54% of all cases, and in 86% of samples with H3F3A and/or ATRX mutations. Screening of a large cohort of gliomas of various grades and histologies (n = 784) showed H3F3A mutations to be specific to GBM and highly prevalent in children and young adults. Furthermore, the presence of H3F3A/ATRX-DAXX/TP53 mutations was strongly associated with alternative lengthening of telomeres and specific gene expression profiles. This is, to our knowledge, the first report to highlight recurrent mutations in a regulatory histone in humans, and our data suggest that defects of the chromatin architecture underlie paediatric and young adult GBM pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone H3 lysine27-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas.”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [3]
In the citing paper
“Indeed, the K27M mutation has been observed to occur in genes encoding all forms of histone H3 (H3.1, H3.2, and H3.3) in human glioma (1,10,24).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [1]
In the citing paper
“ALT is associated with mutations in the chromatin remodeller α-thalassaemia/mental retardation syndrome X-linked (AT R X ) both in vitro and in several human cancers, including glioblastomas162–165.”
From Telomeres in cancer: tumour suppression and genome instability (2017) · cites this paper as [163]
In the citing paper
“The H3.3G34R/V mutated tumours are found almost exclusively in the cerebral hemispheres 101,102 , whereas H3.1K27M tumours are restricted to an area of the brainstem called the pons and H3.3K27M tumours can also be found along the midline of the brain 106 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [106]
In the citing paper
“A heterozygous point mutation of histone H3 occurs in more than 80% of these tumors, and results in a lysine-to-methionine substitution (H3K27M)2,3.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [2]
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Cited by
Items 901–1,000 of 1,001
Jovčevska, I. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00798 · Cited by 48
“3 (71).”
Cintio, F. D., Bo, M. D., Baboçi, L., Mattia, E. D., Polano, M., & Toffoli, G. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.603647 · Cited by 43
Pediatric High Grade Glioma Classification Criteria and Molecular Features of a Case Series
Buccoliero, A. M., Giunti, L., Moscardi, S., Castiglione, F., Provenzano, A., Sardi, I., Scagnet, M., Genitori, L., & Caporalini, C. (2022) · Genes · doi:10.3390/genes13040624 · Cited by 42
“Gly34Arg/Val results in a total reduction of H3K36me2 and H3K36me3 levels [9,14].”
BackgroundProteomics and metabolomics approach in adult and pediatric glioma diagnostics
Pienkowski, T., Kowalczyk, T., Garcia‐Romero, N., Ayuso‐Sacido, Á., & Ciborowski, M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188721 · Cited by 45
Natural Bioactive Compounds Targeting Histone Deacetylases in Human Cancers: Recent Updates
Bouyahya, A., Hachlafi, N. E., Aanniz, T., Bourais, I., Mechchate, H., Benali, T., Shariati, M. A., Burkov, P., Lorenzo, J. M., Wilairatana, P., et al. (2022) · Molecules · doi:10.3390/molecules27082568 · Cited by 42
Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity
López-Pérez, C. A., Franco-Mojica, X., Gaona, R. V., Díaz-Alba, A., Rodríguez-Florido, M. A., & García-Navarro, V. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04024-5 · Cited by 41
Oncohistones: Exposing the nuances and vulnerabilities of epigenetic regulation
Mitchener, M. M., & Muir, T. W. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.07.008 · Cited by 41
Genetic Analysis of Diffuse High‐Grade Astrocytomas in Infancy Defines a Novel Molecular Entity
Gielen, G. H., Gessi, M., Buttarelli, F. R., Baldi, C., Hammes, J., Muehlen, A. Z., Doerner, E., Denkhaus, D., Warmuth‐Metz, M., Giangaspero, F., et al. (2014) · Brain Pathology · doi:10.1111/bpa.12210 · Cited by 41
“Unfortunately, a direct comparison with previous studies is not possible due to the absence of iHGG cases in the more recently published pHGG series with H3F3A/ATRX/DAXX pathway analysis (33), and vice versa, such alterations had not been investigated in detail in previous cytogenetic and molecular studies including i…”
BackgroundResultInfluentialSelf-citationNot just a writer: PRC2 as a chromatin reader
Uckelmann, M., & Davidovich, C. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200728 · Cited by 44
Andrade, A. F., Annett, A., Karimi, E., Topouza, D. G., Rezanejad, M., Liu, Y., McNicholas, M., Santiago, E. G. G., Llivichuzhca-Loja, D., Gehlhaar, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52096-w · Cited by 41
“F), we examined if gene signatures associated with different aspects of immune activation/evasion, in fl ammation, and cell recruitment 23,24 were enriched in immunecompartmentsintumors(SupplementaryData2A –”
MethodInfluentialSelf-citationKim, J. C., Lee, N., Hwu, W., Chien, Y., Fahiminiya, S., Majewski, J., Watkins, D., & Rosenblatt, D. S. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.10.005 · Cited by 40
Self-citationEpigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors
Fontebasso, A. M., Gayden, T., Nikbakht, H., Neirinck, M., Papillon‐Cavanagh, S., Majewski, J., & Jabado, N. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1325-8 · Cited by 41
Self-citationPrimary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases
Li, L., Olar, A., Niu, N., Jiang, Y., Cheng, W., Bian, X., Yang, W., Zhang, J., Yemelyanova, A. V., Malpica, A. L., et al. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000635 · Cited by 40
Histone Lysine-to-Methionine Mutations Reduce Histone Methylation and Cause Developmental Pleiotropy
Sanders, D., Qian, S., Fieweger, R. A., Lü, L., Dowell, J. A., Denu, J. M., & Zhong, X. (2017) · PLANT PHYSIOLOGY · doi:10.1104/pp.16.01499 · Cited by 41
“This is consistent with previous observations of tissue-specific impairment of histonemutation in cancer cells (Schwartzentruber et al., 2012; Behjati et al., 2013; Wu et al., 2014).”
BackgroundResultInfluentialVenkatesh, I., Mehra, V., Wang, Z., Callif, B. L., & Blackmore, M. G. (2018) · Developmental Neurobiology · doi:10.1002/dneu.22605 · Cited by 45
“…alterations in chromatin structure have been implicated in many aspects of human health (Gaspar-Maia et al., 2009; Hargreaves and Crabtree, 2011; Schwartzentruber et al., 2012; Fontebasso et al., 2013) motivating interest in collecting and comparing genome-wide chromatin accessibility changes…”
BackgroundIncorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics
Vega, J. E. V., & Brat, D. J. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000186 · Cited by 40
Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas
Welby, J. P., Kaptzan, T., Wohl, A., Peterson, T. E., Raghunathan, A., Brown, D. A., Gupta, S. K., Zhang, L., & Daniels, D. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00092 · Cited by 43
The Histone H3 Family and Its Deposition Pathways
Ray-Gallet, D., & Almouzni, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-8104-5_2 · Cited by 40
Exosome-based strategies for diagnosis and therapy of glioma cancer
Fath, M. K., Azami, J., Masoudi, A., Mosaddeghi-Heris, R., Rahmani, E., Alavi, F., Bahrami, A. A., Payandeh, Z., Khalesi, B., Dadkhah, M., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02642-7 · Cited by 43
“Activin A receptor type 1 (ACVR1) gene mutations are carried via 20% of DIPGs; however, FGFR1 alterations are mainly associated with thalamic tumors [43, 44].”
BackgroundThe many facets of homologous recombination at telomeres
Claussin, C., & Chang, M. (2015) · Microbial Cell · doi:10.15698/mic2015.09.224 · Cited by 44
“3 are associated with ALT cancers (Heaphy et al., 2011; Schwartzentruber et al., 2012; Lovejoy et al., 2012; Bower et al., 2012).”
Loss of Atrx Sensitizes Cells to DNA Damaging Agents through p53-Mediated Death Pathways
Conte, D., Huh, M. S., Goodall, E. C., Delorme, M., Parks, R. J., & Picketts, D. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052167 · Cited by 44
“Furthermore, ATRX inactivation in human tumors and mouse knockout models result in abnormal telomeres [42,43,44,45].”
BackgroundQaddoumi, I. A., Koçak, M., Panandiker, A. S. P., Armstrong, G. T., Wetmore, C., Crawford, J. R., Lin, T., Boyett, J. M., Kun, L. E., Boop, F. A., et al. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00067 · Cited by 40
“Although a recent study showed a slightly higher occurrence of EGFR amplification and/or mutations in children with HGG (26), larger recent genome-wide molecular analyses demonstrated that these changes occur in only a few cases (27, 28).”
ResultInvited Review: Emerging functions of histone H3 mutations in paediatric diffuse high‐grade gliomas
Kasper, L. H., & Baker, S. J. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12591 · Cited by 40
The cell-cycle choreography of H3 variants shapes the genome
Delaney, K., Weiss, N., & Almouzni, G. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.08.030 · Cited by 40
Histone variants and cellular plasticity
Santoro, S. W., & Dulac, C. G. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.07.005 · Cited by 42
“1) have recently been implicated in a large fraction of human pediatric high-grade astrocytomas, which are particularly aggressive and lethal brain tumors [95, 96].”
BackgroundIdentification of proliferative progenitors associated with prominent postnatal growth of the pons
Lindquist, R. A., Guinto, C. D., Rodas-Rodriguez, J. L., Fuentealba, L. C., Tate, M. C., Rowitch, D. H., & Álvarez-Buylla, A. (2016) · Nature Communications · doi:10.1038/ncomms11628 · Cited by 39
“Most DIPGs also contain a mutation in Histone H3 at lysine 27 (refs 57,58), which might epigenetically trap cells in a progenitor state 50 and prevent repression of Olig2 or Sox2; one study showed that a H3K27M DIPG patient tumour-derived cell line had increased Olig2 expression correlated with…”
Pediatric Brain Tumors: An Update
Segal, D., & Karajannis, M. A. (2016) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2016.04.004 · Cited by 46
Historadiological correlations in high-grade glioma with the histone 3.3 G34R mutation
Puntonet, J., Dangouloff‐Ros, V., Saffroy, R., Pagès, M., Andreiuolo, F. D. M., Grill, J., Puget, S., Boddaert, N., & Varlet, P. (2018) · Journal of Neuroradiology · doi:10.1016/j.neurad.2018.02.006 · Cited by 40
Defining tumor-associated vascular heterogeneity in pediatric high-grade and diffuse midline gliomas
Wei, X., Meel, M. H., Breur, M., Bugiani, M., Hulleman, E., & Phoenix, T. N. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01243-1 · Cited by 41
Yoon, J., Grinchuk, O. V., Tirado-Magallanes, R., Ngian, Z., Tay, E. X. Y., Chuah, Y. H., Lee, B. W. L., Jia, F., Crasta, K., Ong, C., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-021-00926-5 · Cited by 42
Gallardo, A., Molina, A., Asenjo, H. G., López-Onieva, L., Martorell‐Marugán, J., Espinosa-Martínez, M., Griñán‐Lisón, C., Álvarez-Pérez, J. C., Cara, F. E., Navarro-Marchal, S. A., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02375-x · Cited by 40
Moffatt, P., Amor, M. B., Glorieux, F. H., Roschger, P., Klaushofer, K., Schwartzentruber, J., Paterson, A. D., Hu, P., Marshall, C. R., Fahiminiya, S., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.12.001 · Cited by 44
Self-citationMartinez, P. J., Green, A. L., & Borden, M. A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.037 · Cited by 41
Mbah, N. E., Myers, A. L., Sajjakulnukit, P., Chung, C., Thompson, J. K., Hong, H. S., Giza, H., Dang, D., Nwosu, Z. C., Shan, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52973-4 · Cited by 41
New insights and challenges in mismatch repair: Getting over the chromatin hurdle
Li, G. (2014) · DNA repair · doi:10.1016/j.dnarep.2014.03.027 · Cited by 39
“3G34R/V amino acid substitutions as the driver mutations for pediatric glioblastoma [75, 76].”
BackgroundLee, J.-S., & Zhang, Z. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600509113 · Cited by 48
Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours
Haque, F., Varlet, P., Puntonet, J., Storer, L. C. D., Bountali, A., Rahman, R., Grill, J., Carcaboso, A. M., Jones, C., Layfield, R., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0449-1 · Cited by 39
SOX2 immunity and tissue resident memory in children and young adults with glioma
Vasquez, J. C., Huttner, A. J., Zhang, L., Marks, A. M., Chan, A., Baehring, J. M., Kahle, K. T., & Dhodapkar, K. M. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2515-8 · Cited by 38
Neurological update: gliomas and other primary brain tumours in adults
Brandner, S., & Jaunmuktane, Z. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8652-3 · Cited by 45
Histone H3.3 sub-variant H3mm7 is required for normal skeletal muscle regeneration
Harada, A., Maehara, K., Ono, Y., Taguchi, H., Yoshioka, K., Kitajima, Y., Xie, Y., Sato, Y., Iwasaki, T., Nogami, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03845-1 · Cited by 40
Fellenberg, J., Sähr, H., Mancarella, D., Plass, C., Lindroth, A. M., Westhauser, F., Lehner, B., & Ewerbeck, V. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.001 · Cited by 39
Self-citationSingh, P. K. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.069 · Cited by 39
Pladevall‐Morera, D., Munk, S., Ingham, A., Garribba, L., Albers, E., Liu, Y., Olsen, J. V., & Lopez-Contreras, A. J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz510 · Cited by 38
“On the other hand, mutations in ATRX are strongly associated with pediatric glioblastoma (58).”
BackgroundBockmayr, M. L., Klauschen, F., Maire, C. L., Rutkowski, S., Westphal, M., Lamszus, K., Schüller, U., & Mohme, M. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0939 · Cited by 39
Barresi, V., Simbolo, M., Mafficini, A., Piredda, M. L., Caffo, M., Cardali, S. M., Germanò, A., Cingarlini, S., Ghimenton, C., & Scarpa, A. (2019) · Cancers · doi:10.3390/cancers11091279 · Cited by 40
The prognostic significance of further genotyping H3G34 diffuse hemispheric gliomas
Vuong, H. G., Le, H. T., & Dunn, I. F. (2022) · Cancer · doi:10.1002/cncr.34156 · Cited by 40
“3 variants, resulting in glycine- toarginine (G34R) or glycine- to- valine (G34V) amino acid substitutions.(7,8) These mutations generate posttranslational modifications by altering the methylation status of proximal lysine at position 36.”
BackgroundSeabrook, A., Wijewardene, A. A., Sousa, S. D., Wong, T., Sheriff, N., Gill, A. J., Iyer, R., Field, M., Luxford, C., Clifton-Bligh, R. J., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac162 · Cited by 43
Pereira, K. N. E., Shan, J., Licht, J. D., & Bennett, R. L. (2023) · Biochemical Society Transactions · doi:10.1042/bst20210567 · Cited by 41
Franz, M., Payne, W. G., Xing, L., Naidu, D. K., Salas, R., Marshall, V. S., Trumpower, C., Smith, C. A., Steed, D. L., & Robson, M. C. (2008) · PubMed Central · Cited by 41
Modeling and Targeting MYC Genes in Childhood Brain Tumors
Hutter, S., Bolin, S., Weishaupt, H., & Swartling, F. J. (2017) · Genes · doi:10.3390/genes8040107 · Cited by 39
“3 variant encoding H3F3A gene [33,37], the latter of which presents a frequent phenotype reported to account for 30%–50% of pediatric GBMs [33,38].”
InfluentialLiquid Biopsy for Glioma Using Cell-Free DNA in Cerebrospinal Fluid
Otsuji, R., Fujioka, Y., Hata, N., Kuga, D., Hatae, R., Sangatsuda, Y., Nakamizo, A., Mizoguchi, M., & Yoshimoto, K. (2024) · Cancers · doi:10.3390/cancers16051009 · Cited by 40
“Another mutation in H3F3A, G34R/V, in which glycine 34 is replaced by arginine or valine, has been identified as a cause of diffuse hemispheric glioma in adolescents and young adults [145].”
BackgroundEisenstat, D. D., Pollack, I. F., Demers, A. A., Sapp, M. V., Lambert, P. J., Weisfeld‐Adams, J. D., Burger, P. C., Gilles, F. H., Davis, R. L., Packer, R. J., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1669-x · Cited by 37
Examining the impact of gene variants on histone lysine methylation
Rechem, C. V., & Whetstine, J. R. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.05.014 · Cited by 41
Breaking new ground: Digging into TERRA function
Maicher, A., Lockhart, A., & Luke, B. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.012 · Cited by 43
Mozzetta, C., Pontis, J., & Ait‐Si‐Ali, S. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.6116 · Cited by 40
Stem cell cultures derived from pediatric brain tumors accurately model the originating tumors
Wenger, A., Larsson, S., Danielsson, A., Elbæk, K. J., Kettunen, P., Tisell, M., Sabel, M., Lannering, B., Nordborg, C., Schepke, E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14826 · Cited by 38
“Methylation profiling can be used to diagnose and subgroup pediatric brain tumors [2, 4, 19, 33, 34] and the functional role of epigenetic alterations in brain tumors now needs to be uncovered.”
BackgroundHan, H. J., Jain, P., & Resnick, A. C. (2017) · Bone · doi:10.1016/j.bone.2017.08.001 · Cited by 41
Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?
Pompili, L., Leonetti, C., Biroccio, A., & Salvati, E. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0657-3 · Cited by 42
“In addition, ALT mechanisms have been also found in adult somatic cells of different hystotypes [13, 14], than it is speculated that ALT may be a constitutive component of telomeres that coexists already with Telomerase Activation (TA) as a back-up TMM during evolution in most eukaryotes [15].”
InfluentialTeng, Y. D., Abd‐El‐Barr, M. M., Wang, L., Hajiali, H., Wu, L., & ZAFONTE, R. D. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.09.010 · Cited by 37
Surprising phenotypic diversity of cancer-associated mutations of Gly 34 in the histone H3 tail
Lowe, B. R., Yadav, R. K., Henry, R. A., Schreiner, P. A., Matsuda, A., Fernandez, A. G., Finkelstein, D., Campbell, M., Kallappagoudar, S., Jablonowski, C. M., et al. (2021) · eLife · doi:10.7554/elife.65369 · Cited by 38
“3 chaperone and remodeler proteins DAXX and ATRX (Bjerke et al., 2013; Korshunov et al., 2016; Schwartzentruber et al., 2012; Wu et al., 2012), is currently unclear.”
BackgroundInfluentialPrognostic Implication of Patient Age in H3K27M-Mutant Midline Gliomas
Vuong, H. G., Ngo, T. N. M., Le, H. T., Jea, A. H., Hrachova, M., Battiste, J. D., McNall‐Knapp, R. Y., & Dunn, I. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.858148 · Cited by 37
“Despite aggressive therapeutic approaches and advances in chemoradiotherapy and targeted therapy regimens, there has been no survival improvement for patients with H3K27M mutations over the recent years (3, 8).”
BackgroundResultNew twists to the ALTernative endings at telomeres
Bhargava, R., Lynskey, M. L., & O’Sullivan, R. J. (2022) · DNA repair · doi:10.1016/j.dnarep.2022.103342 · Cited by 41
Advances in the Treatment of Pediatric Brain Tumors
Kulubya, E. S., Kercher, M. J., Phillips, H. W., Antony, R., & Edwards, M. S. B. (2022) · Children · doi:10.3390/children10010062 · Cited by 40
Minturn, J. E., & Fisher, M. J. (2013) · Current Treatment Options in Neurology · doi:10.1007/s11940-013-0225-x · Cited by 46
DeNizio, J. E., Elsässer, S. J., & Black, B. E. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku090 · Cited by 37
Bithalamic gliomas may be molecularly distinct from their unilateral high‐grade counterparts
Broniscer, A., Hwang, S. N., Chamdine, O., Lin, T., Pounds, S. B., Onar‐Thomas, A., Chi, L., Shurtleff, S. A., Allen, S. J., Gajjar, A. J., et al. (2017) · Brain Pathology · doi:10.1111/bpa.12484 · Cited by 40
“G34 in our patients was not surprising because they predominantly occur in tumors arising in the cerebral cortex (21, 25, 30).”
BackgroundResultHistone H3 Mutations in Pediatric Brain TumorsPreprint
Liu, X., McEachron, T. A., Schwartzentruber, J., & Wu, G. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018689 · Cited by 37
“frequently observed in tumors with ATRX mutations (Lovejoy et al. 2012; Schwartzentruber et al. 2012).”
BackgroundSelf-citationShaping Chromatin in the Nucleus: The Bricks and the Architects
Sitbon, D., Podsypanina, K., Yadav, T., & Almouzni, G. (2017) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2017.82.033753 · Cited by 40
“Notably, point mutations in human H3 variants, such as K27M and G34R/V (Schwartzentruber et al. 2012; Wu et al. 2012), or their associated chaperones (Heaphy et al.”
BackgroundInfluentialReversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma
Zhao, G., Newbury, P. A., Ishi, Y., Chekalin, E., Zeng, B., Glicksberg, B. S., Wen, A., Paithankar, S., Sasaki, T., Suri, A., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01463-z · Cited by 37
Bogumil, H., Sill, M., Schrimpf, D., Ismer, B., Blume, C., Rahmanzade, R., Hinz, F. E., Cherkezov, A., Banan, R., Friedel, D., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02558-0 · Cited by 36
Self-citationDiffuse midline glioma invasion and metastasis rely on cell-autonomous signaling
Bruschi, M., Midjek, L., Ajlil, Y., Vairy, S., Lancien, M., Ghermaoui, S., Kergrohen, T., Verreault, M., Idbaïh, A., de Biagi, C. A. O., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad161 · Cited by 38
“18 This is especially true in the case of DMG, in which polycomb repressive complex 2 in-activation impairs differentiation and promotes the accumulation of stem-like tumor cells with progenitor identity, to ultimately comprise up to 80% of the tumor.”
BackgroundChromatin Dynamics in Vivo: A Game of Musical Chairs
Melters, D. P., Nye, J., Zhao, H., & Dalal, Y. (2015) · Genes · doi:10.3390/genes6030751 · Cited by 40
“Dramatic chromatin rearrangements and mis-regulation of histone variants [61,166,167] are a feature of cancer cells [168].”
Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities
Glod, J. W., Rahme, G. J., Kaur, H., Raabe, E. H., Hwang, E. I., & Israel, M. A. (2016) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000551 · Cited by 37
Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas
Juratli, T. A., Qin, N., Cahill, D. P., & Filbin, M. G. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.006 · Cited by 39
“3 chromatin remodeling pathway were identified in up to 60% of all pediatric midline gliomas, resulting in the disruptions of epigenetic mechanisms (Schwartzentruber et al., 2012; Sturm et al., 2012; Wu et al., 2012, 2014).”
BackgroundInfluentialGenetics of Common Pediatric Brain Tumors
Malbari, F., & Lindsay, H. (2019) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2019.08.004 · Cited by 42
WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial
Varlet, P., Teuff, G. L., Deley, M. L., Giangaspero, F., Haberler, C., Jacques, T. S., Figarella‐Branger, D., Pietsch, T., Andreiuolo, F. D. M., Deroulers, C., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz142 · Cited by 37
Guerra‐García, P., Marshall, L. V., Cockle, J. V., Ramachandran, P. V., Saran, F. H., Jones, C., & Carceller, F. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28011 · Cited by 38
Aptamers: Novel Therapeutics and Potential Role in Neuro-Oncology
Amero, P., Khatua, S., Rodriguez‐Aguayo, C., & Lopez‐Berestein, G. (2020) · Cancers · doi:10.3390/cancers12102889 · Cited by 39
“—showed that mutations in genes that encode histones, the spool-like proteins around which DNA is wound, contribute to high-grade glioma [105,106].”
BackgroundAdvances in Targeted Therapies for Pediatric Brain Tumors
Mueller, T., Stücklin, A. G., Postlmayr, A., Metzger, S. M., Gerber, N. U., Kline, C., Grotzer, M. A., Nazarian, J., & Mueller, S. (2020) · Current Treatment Options in Neurology · doi:10.1007/s11940-020-00651-3 · Cited by 46
Genome-guided discovery of cancer therapeutic targets
Konda, P., Garinet, S., Allen, E. M. V., & Viswanathan, S. R. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112978 · Cited by 36
Molecular characteristics of pediatric high-grade gliomas
Chamdine, O., & Gajjar, A. J. (2014) · CNS Oncology · doi:10.2217/cns.14.43 · Cited by 40
The Contribution of Mass Spectrometry-Based Proteomics to Understanding Epigenetics
Noberini, R., Sigismondo, G., & Bonaldi, T. (2015) · Epigenomics · doi:10.2217/epi.15.108 · Cited by 38
Schwark, K., Messinger, D., Cummings, J. R., Bradin, J., Kawakibi, A. R., Babila, C. M., Lyons, S., Ji, S., Cartaxo, R. T., Kong, S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.922928 · Cited by 45
Molecular markers in pediatric neuro-oncology
Ichimura, K., Nishikawa, R., & Matsutani, M. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos204 · Cited by 36
“Furthermore, in a series of pediatric GBM with predominantly non-BS location, mutations of a-thalassaemia/ mental retardation syndrome X-linked (ATRX) or death-domain associated protein (DAXX) were found in 31% of tumors, some of them concurrently with H3F3A mutations.(24) Overall, 44% of pediatric GBM in this series…”
BackgroundResultSelf-citationModeling Cancer with Pluripotent Stem Cells
Gingold, J. A., Zhou, R., Lemischka, I. R., & Lee, D. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.07.007 · Cited by 40
“3K27M) is commonly detected in patients with DIPGs and is associated with poor survival [39, 40].”
BackgroundExtending the Neuroanatomic Territory of Diffuse Midline Glioma, K27M Mutant: Pineal Region Origin
Gilbert, A., Zaky, W. T., Gökden, M., Fuller, C. E., Öcal, E., Leeds, N. E., & Fuller, G. N. (2017) · Pediatric Neurosurgery · doi:10.1159/000481513 · Cited by 35
Baril, S. A., Koenig, A. L., Krone, M. W., Albanese, K. I., He, C. Q., Lee, G. Y., Houk, K. N., Waters, M. L., & Brustad, E. M. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b09223 · Cited by 35
Gill, P., Kim, E., Chua, T. C., Clifton-Bligh, R. J., Nahm, C. B., Mittal, A., Gill, A. J., & Samra, J. S. (2019) · Endocrine Pathology · doi:10.1007/s12022-019-9570-y · Cited by 35
Pediatric hemispheric high-grade glioma: targeting the future
Coleman, C., Stoller, S., Grotzer, M. A., Stücklin, A. G., Nazarian, J., & Mueller, S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09850-5 · Cited by 38
Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities
Haase, S., Núñez, F. M., Gauss, J. C., Thompson, S., Brumley, E. K., Lowenstein, P. R., & Castro, M. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249654 · Cited by 35
“The ALT phenotype of G34R/V is strongly correlated to the loss of TP53/ATRX/DAXX; however, the role of TP53 in this process is not yet clear [18,19].”
BackgroundInfluentialWang, Z., Guo, X., Gao, L., Wang, Y., Guo, Y. C., Xing, B., & Ma, W. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.12.012 · Cited by 38
A conserved BAH module within mammalian BAHD1 connects H3K27me3 to Polycomb gene silencing
Fan, H., Guo, Y., Tsai, Y., Storey, A. J., Kim, A., Gong, W., Edmondson, R. D., Mackintosh, S. G., Li, H., Byrum, S. D., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab210 · Cited by 38
Imaging of brain tumors in children: the basics—a narrative review
Resende, L. L., & Alves, C. (2021) · Translational Pediatrics · doi:10.21037/tp-20-285 · Cited by 36
“Notably, the critical distinction that best describes the diffuse infiltrating gliomas in children is the identification of somatic histone mutations, which are not found in adults (46).”
BackgroundDNA methylation and histone variants in aging and cancer
Mangelinck, A., & Mann, C. (2021) · International review of cytology · doi:10.1016/bs.ircmb.2021.06.002 · Cited by 41
Recent Advances in Pediatric Cancer Research
McEachron, T. A., & Helman, L. J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1191 · Cited by 40
“Histone H3K27 Since the first reports of somatic histone H3 mutations at lysine 27 (H3K27M) and glycine 34 (H3G34) in pediatric HGG in 2012, the interest in these “onco-histones” has sparked numerous investigations aimed at understanding their role in tumorigenesis (110, 111).”
BackgroundLeszczyńska, K. B., Jayaprakash, C., Kaminska, B., & Mieczkowski, J. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.742561 · Cited by 37
Bočkaj, I., Martini, T. E. I., Magalhães, E. S. D. C., Bakker, P. L., Boer, T. M.-D., Armandari, I., Meuleman, S. L., Mondria, M. T., Stok, C., Kok, Y. P., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009868 · Cited by 35
Genomic profiling and prognostic factors of H3 K27M ‐mutant spinal cord diffuse glioma
Chai, R., Yan, H., An, S., Pang, B., Chen, H., Mu, Q., Zhang, K., Zhang, Y.-W., Liu, Y., Liu, X., et al. (2023) · Brain Pathology · doi:10.1111/bpa.13153 · Cited by 41
“Most patients with H3 K27M-mutant spinal cord diffuse glioma are adults, and their prognosis is better than that of patients with H3 K27M-mutant brain stem tumors, mainly pediatric patients [6, 9, 17, 19].”
BackgroundSelf-citationJha, P., Patric, I. R. P., Shukla, S. K., Pathak, P., Pal, J., Sharma, V., Thinagararanjan, S., Santosh, V., Suri, V. S., Sharma, M. C., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou113 · Cited by 35
Maeda, S., Ohka, F., Okuno, Y., Aoki, K., Motomura, K., Takeuchi, K., Hironao, K., Yanagisawa, N., Sato, S., Yamaguchi, J., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0882-4 · Cited by 50
Metadata
- Authors
- Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., Hovestadt, V., Albrecht, S., Kool, M., Nantel, A., Konermann, C., Lindroth, A., Jäger, N., Rausch, T., Ryzhova, M., Korbel, J. O., Hielscher, T., Hauser, P., Garami, M., Klekner, A., Bognar, L., Ebinger, M., Schuhmann, M. U., Scheurlen, W., Pekrun, A., Frühwald, M. C., Roggendorf, W., Kramm, C., Dürken, M., Atkinson, J., Lepage, P., Montpetit, A., Zakrzewska, M., Zakrzewski, K., Liberski, P. P., Dong, Z., Siegel, P., Kulozik, A. E., Zapatka, M., Guha, A., Malkin, D., Felsberg, J., Reifenberger, G., von Deimling, A., Ichimura, K., Collins, V. P., Witt, H., Milde, T., Witt, O., Zhang, C., Castelo-Branco, P., Lichter, P., Faury, D., Tabori, U., Plass, C., Majewski, J., Pfister, S. M., & Jabado, N.
- Affiliations
- McGill University and Génome Québec Innovation Centre (CA)
- German Cancer Research Center (DE)
- McGill University (CA)
- Montreal Children's Hospital (CA)
- European Molecular Biology Laboratory (DE)
- Burdenko Neurosurgery Institute (RU)
- University Children's Hospital Tübingen (DE)
- Universitätsklinikum Tübingen (DE)
- Cnopf´sche Kinderklinik (DE)
- Prof. Hess Kinderklinik (DE)
- University Hospital Augsburg (DE)
- University of Würzburg (DE)
- University Hospital in Halle (DE)
- Medical University of Lodz (PL)
- University Hospital Heidelberg (DE)
- University of Toronto (CA)
- Heinrich Heine University Düsseldorf (DE)
- University of Cambridge (GB)
- McGill University Health Centre (CA)
- Corresponding author
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- ORCID
- Schwartzentruber, Jeremy
- Korshunov, Andrey
- Jones, David T. W.
- Pfaff, Elke
- Sturm, Dominik
- Hovestadt, Volker
- Albrecht, Steffen
- Kool, Marcel
- Lindroth, Anders
- Jäger, Natalie
- Rausch, Tobias
- Ryzhova, Marina
- Korbel, Jan O.
- Hielscher, Thomas
- Ebinger, Martin
- Schuhmann, Martin U.
- Frühwald, Michael C.
- Dürken, Matthias
- Atkinson, Jeffrey
- Lepage, Pierre
- Zakrzewska, Magdalena
- Liberski, Pawel P.
- Siegel, Peter
- Kulozik, Andreas E.
- Zapatka, Marc
- Guha, Abhijit
- Malkin, David
- Felsberg, Jörg
- Reifenberger, Guido
- Ichimura, Koichi
- Collins, V. Peter
- Witt, Hendrik
- Milde, Till
- Witt, Olaf
- Zhang, Cindy
- Lichter, Peter
- Faury, Damien
- Tabori, Uri
- Plass, Christoph
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- Venue
- Nature
- Published
- 2012-01-29
- Volume
- 482
- Issue
- 7384
- Pages
- 226-231
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2158233796
- Cited by
- 2,631
- References
- 35
- Citations by year
- 2026: 109 · 2025: 138 · 2024: 188 · 2023: 189 · 2022: 200 · 2021: 226 · 2020: 238 · 2019: 188 · 2018: 166 · 2017: 200 · 2016: 174 · 2015: 165 · 2014: 189 · 2013: 166 · 2012: 90
- FWCI
- 92.99
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-03-28)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- NPARC (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Funders
- Cancer Research Institute
- Genome Canada
- Brain Tumour Charity (10/106)
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- H3F3A mutation, histone H3.3, ATRX mutation, chromatin remodeling, somatic mutations, TP53 mutation, H3K27M mutation, histone modifications, histone deacetylase inhibitors
- MeSH terms
- X-linked Nuclear Protein, Base Sequence, Child, Chromatin, DNA Mutational Analysis, DNA Helicases, Glioblastoma, Histones, Humans, Molecular Sequence Data, Mutation, Nuclear Proteins, Tumor Suppressor Protein p53, Telomere, Molecular Chaperones, Gene Expression Profiling, Chromatin Assembly and Disassembly, Adaptor Proteins, Signal Transducing, Co-Repressor Proteins, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.